Survey on the implementation status and reproductive outcomes of oocyte and ovarian tissue cryopreservation in Japan: Historical comparison with nationwide surveys
Journal of Obstetrics and Gynaecology Research · 2024
DOI: 10.1111/jog.15893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2024. Verfasst von Seido Takae und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan. Hauptthemen laut MEDLINE: Cryopreservation, Fertility Preservation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare, Japan, Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
Purpose
To clarify the reproductive outcomes of fertility preservation (FP) treatment.
Methods
We conducted a mailed‐in questionnaire survey at institutions certified by the Japan Society of Obstetrics and Gynecology to investigate the number of oocyte cryopreservations (OC) and ovarian tissue cryopreservations (OTC) performed from December 2016 to the end of 2020. And, we conducted a detailed investigation of cases in which frozen specimens were used during the investigation period, and made historical comparisons with previous nationwide studies.
Results
Responses were received from 114 out of 150 facilities (response rate: 76.0%) for OC and 43 out of 51 for OTC (response rate: 84.3%). Breast cancer was the most common disease among patients whose FP specimens were used. During the study period, 1237 OCs and 198 OTCs were performed. In addition, 57 cycles of embryo transfer (ET) using cryopreserved oocytes and 12 cases of ovarian tissue transplantation (OTT) were performed. The mean age of patients who underwent ET using cryopreserved oocytes was 34.8 (±5.8) years, with a median age of 36 years. The pregnancy rate per ET using cryopreserved oocytes was 26.3% and the live birth rate (LBR) was 17.5%. Further, the LBR per patient was 43.3%, and the pregnancy rate following OTTs was 33.3%. Also, controlled ovarian stimulation using the random start method or the combination of aromatase inhibitors had no effect on pregnancy outcome.
Conclusion
Implementation of both OCs and OTCs have markedly increased over time in Japan, with comparable reproductive outcomes as other reports.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan.
- Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.
ORCID-Profile: Seido Takae, Miyuki Harada, Yutaka Osuga, Nao Suzuki
Förderung
- Ministry of Health, Labour and Welfare, Japan
- Ministry of Health, Labour and Welfare
Zitieren
APA
Takae, S., Harada, M., Nakamura, K., Furuyama, S., Ono, M., Osuga, Y., & Suzuki, N. (2024). Survey on the implementation status and reproductive outcomes of oocyte and ovarian tissue cryopreservation in Japan: Historical comparison with nationwide surveys. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15893
Vancouver
Takae S, Harada M, Nakamura K, Furuyama S, Ono M, Osuga Y, et al. Survey on the implementation status and reproductive outcomes of oocyte and ovarian tissue cryopreservation in Japan: Historical comparison with nationwide surveys. Journal of Obstetrics and Gynaecology Research. 2024. doi:10.1111/jog.15893
BibTeX
@article{Takae2024,
author = {Takae, Seido and Harada, Miyuki and Nakamura, Kentaro and Furuyama, Sayako and Ono, Masanori and Osuga, Yutaka and Suzuki, Nao},
title = {Survey on the implementation status and reproductive outcomes of oocyte and ovarian tissue cryopreservation in Japan: Historical comparison with nationwide surveys},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2024},
doi = {10.1111/jog.15893}
}
EUVIMED